BACKGROUND: To examine the effect of body mass index (BMI) on clinicopathologic factors and long-term survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. METHODS: Data on BMI, weight loss, operative details, surgical pathology, and long-term survival were collected on 795 patients who underwent pancreaticoduodenectomy. Patients were categorized as obese (BMI > 30 kg/m(2)), overweight (BMI 25 to <30 kg/m(2)), or normal weight (BMI < 25 kg/m(2)) and compared using univariate and multivariate analyses. RESULTS: At the time of surgery, 14% of patients were obese, 33% overweight, and 53% normal weight. Overall, 32% of patients had preoperative weight loss of >10%. There were no differences in operative times among the groups; however, higher BMI was associated with increased risk of blood loss (P < 0.001) and pancreatic fistula (P = 0.01). On pathologic analysis, BMI was not associated with tumor stage or number of lymph nodes harvested (both P > 0.05). Higher BMI patients had a lower incidence of a positive retroperitoneal/uncinate margin versus normal weight patients (P = 0.03). Perioperative morbidity and mortality were similar among the groups. Obese and overweight patients had better 5-year survival (22% and 22%, respectively) versus normal weight patients (15%; P = 0.02). After adjusting for other prognostic factors, as well as preoperative weight loss, higher BMI remained independently associated with improved cancer-specific survival (overweight: hazard ratio, 0.68; obese: hazard ratio, 0.72; both P < 0.05). CONCLUSION: Obese patients had similar tumor-specific characteristics, as well as perioperative outcomes, compared with normal weight patients. However, obese patients undergoing pancreaticoduodenectomy for pancreatic cancer had an improved long-term survival independent of known clinicopathologic factors.
BACKGROUND: To examine the effect of body mass index (BMI) on clinicopathologic factors and long-term survival in patients undergoing pancreaticoduodenectomy for pancreatic adenocarcinoma. METHODS: Data on BMI, weight loss, operative details, surgical pathology, and long-term survival were collected on 795 patients who underwent pancreaticoduodenectomy. Patients were categorized as obese (BMI > 30 kg/m(2)), overweight (BMI 25 to <30 kg/m(2)), or normal weight (BMI < 25 kg/m(2)) and compared using univariate and multivariate analyses. RESULTS: At the time of surgery, 14% of patients were obese, 33% overweight, and 53% normal weight. Overall, 32% of patients had preoperative weight loss of >10%. There were no differences in operative times among the groups; however, higher BMI was associated with increased risk of blood loss (P < 0.001) and pancreatic fistula (P = 0.01). On pathologic analysis, BMI was not associated with tumor stage or number of lymph nodes harvested (both P > 0.05). Higher BMI patients had a lower incidence of a positive retroperitoneal/uncinate margin versus normal weight patients (P = 0.03). Perioperative morbidity and mortality were similar among the groups. Obese and overweight patients had better 5-year survival (22% and 22%, respectively) versus normal weight patients (15%; P = 0.02). After adjusting for other prognostic factors, as well as preoperative weight loss, higher BMI remained independently associated with improved cancer-specific survival (overweight: hazard ratio, 0.68; obese: hazard ratio, 0.72; both P < 0.05). CONCLUSION:Obesepatients had similar tumor-specific characteristics, as well as perioperative outcomes, compared with normal weight patients. However, obesepatients undergoing pancreaticoduodenectomy for pancreatic cancer had an improved long-term survival independent of known clinicopathologic factors.
Authors: Jordan M Winter; John L Cameron; Kurtis A Campbell; David C Chang; Taylor S Riall; Richard D Schulick; Michael A Choti; JoAnn Coleman; Mary B Hodgin; Patricia K Sauter; Christopher J Sonnenday; Christopher L Wolfgang; Michael R Marohn; Charles J Yeo Journal: J Gastrointest Surg Date: 2006-11 Impact factor: 3.452
Authors: Rebekah R White; H Bill Xie; Marcia R Gottfried; Brian G Czito; Herbert I Hurwitz; Michael A Morse; Gerald C Blobe; Erik K Paulson; John Baillie; M Stanley Branch; Paul S Jowell; Bryan M Clary; Theodore N Pappas; Douglas S Tyler Journal: Ann Surg Oncol Date: 2005-03-03 Impact factor: 5.344
Authors: Cynthia L Ogden; Margaret D Carroll; Lester R Curtin; Margaret A McDowell; Carolyn J Tabak; Katherine M Flegal Journal: JAMA Date: 2006-04-05 Impact factor: 56.272
Authors: Michael G House; Yuman Fong; Dean J Arnaoutakis; Rohit Sharma; Corinne B Winston; Mladjan Protic; Mithat Gonen; Sara H Olson; Robert C Kurtz; Murray F Brennan; Peter J Allen Journal: J Gastrointest Surg Date: 2007-12-01 Impact factor: 3.452
Authors: Timothy K Williams; Ernest L Rosato; Eugene P Kennedy; Karen A Chojnacki; Jocelyn Andrel; Terry Hyslop; Cataldo Doria; Patricia K Sauter; Jordan Bloom; Charles J Yeo; Adam C Berger Journal: J Am Coll Surg Date: 2008-12-18 Impact factor: 6.113
Authors: Ashish M Kamat; Ryan P Shock; Yoshio Naya; Charles J Rosser; Joel W Slaton; Louis L Pisters Journal: Urology Date: 2004-01 Impact factor: 2.649
Authors: Robert M Cannon; Ryan LeGrand; Ryaz B Chagpar; Syed A Ahmad; Rebecca McClaine; Hong Jin Kim; Christopher Rupp; Cliff S Cho; Adam Brinkman; Sharon Weber; Emily R Winslow; David A Kooby; Carrie K Chu; Charles A Staley; Ian Glenn; William G Hawkins; Alexander A Parikh; Nipun B Merchant; Kelly M McMasters; Robert C G Martin; Glenda G Callender; Charles R Scoggins Journal: HPB (Oxford) Date: 2012-01-19 Impact factor: 3.647
Authors: Marco Del Chiaro; Elena Rangelova; Christoph Ansorge; John Blomberg; Ralf Segersvärd Journal: World J Gastrointest Pathophysiol Date: 2013-05-15
Authors: Raphael L C Araujo; Ami M Karkar; Peter J Allen; Mithat Gönen; Joanne F Chou; Murray F Brennan; Leslie H Blumgart; Michael I D'Angelica; Ronald P DeMatteo; Daniel G Coit; Yuman Fong; William R Jarnagin Journal: HPB (Oxford) Date: 2013-04-18 Impact factor: 3.647